Calliditas Therapeutics AB (NAS:CALT)

$ 40.0001 -0.1599 (-0.4%) Market Cap: 1.08 Bil Enterprise Value: 1.10 Bil PE Ratio: 0 PB Ratio: 104.30 GF Score: 33/100

Q2 2024 Calliditas Therapeutics AB Earnings Call Transcript
Aug 13, 2024

$39.24 (+0.14%)

Earnings
Q1 2024 Calliditas Therapeutics AB Earnings Call Transcript
May 23, 2024

$22.75 (+4.79%)

Earnings
Q4 2023 Calliditas Therapeutics AB Earnings Call Transcript
Feb 21, 2024

$20.3 (-2.96%)

Earnings
Q3 2023 Calliditas Therapeutics AB Earnings Call Transcript
Nov 07, 2023

$15.89 (-3.17%)

Earnings
Q2 2023 Calliditas Therapeutics AB Earnings Call Transcript
Aug 17, 2023

$15.9 (-16.09%)

Earnings
Q1 2023 Calliditas Therapeutics AB Earnings Call Transcript
May 16, 2023

$21.17 (-16.98%)

Earnings
Calliditas Therapeutics AB Nefigard Topline Data Presentation Transcript
Mar 13, 2023
Q4 2022 Calliditas Therapeutics AB Earnings Call Transcript
Feb 23, 2023

$19.99 (+11.06%)

Earnings
Calliditas Therapeutics AB Fireside Chat with Everest Medicines Ltd Transcript
Dec 14, 2022
Q3 2022 Calliditas Therapeutics AB Earnings Call Transcript
Nov 14, 2022

$15 (-1.64%)

Earnings
Calliditas Therapeutics AB KOL Webinar Transcript
Nov 08, 2022
Q2 2022 Calliditas Therapeutics AB Earnings Call Transcript
Aug 18, 2022

$18 (-15.13%)

Earnings
Q1 2022 Calliditas Therapeutics AB Earnings Call Transcript
May 18, 2022

$15.99 (+5.20%)

Earnings
Q4 2021 Calliditas Therapeutics AB Earnings Call Transcript
Feb 24, 2022

$17.91 (+1.13%)

Earnings
Calliditas Therapeutics AB -FDA Approval of TARPEYO to Reduce Proteinuria in IgA Nephropathy Transcript
Dec 16, 2021
Q3 2021 Calliditas Therapeutics AB Earnings Call Transcript
Nov 18, 2021

$17.7 (+6.88%)

Earnings
Q2 2021 Calliditas Therapeutics AB Earnings Call Transcript
Aug 19, 2021

$21.91 (-0.45%)

Earnings
Q1 2021 Calliditas Therapeutics AB Earnings Call Transcript
May 18, 2021

$29.08 (-0.14%)

Earnings
Calliditas Therapeutics AB (publ) - Special Call Transcript
Mar 10, 2021
Q4 2020 Calliditas Therapeutics AB Earnings Call Transcript
Feb 18, 2021

$30.3 (-5.02%)

Earnings
Calliditas Therapeutics AB Corporate Analyst Meeting Transcript
Jan 20, 2021
Q3 2020 Calliditas Therapeutics AB Earnings Call Transcript
Nov 12, 2020

$32.7 (-2.39%)

Earnings
Calliditas Therapeutics AB (publ) - Special Call Transcript
Nov 09, 2020
Q2 2020 Calliditas Therapeutics AB Earnings Call Transcript
Aug 13, 2020

$22.03 (-4.47%)

Earnings
Q1 2020 Calliditas Therapeutics AB Earnings Call Transcript
May 14, 2020

Earnings

Q4 2020 Calliditas Therapeutics AB Earnings Call Transcript

Feb 18, 2021 / 01:30PM GMT

Release Date Price: $30.3 (-5.02%)

Transcript

Operator

Ladies and gentlemen welcome to the Calliditas Therapeutics Q4 2020. Today, I'm pleased to present CEO, Renee Lucander; and CFO, Fredrik Johansson.

(Operator Instructions)

Renee, please begin.

Renee Aguiar;Lucander;publ;CEO

Calliditas Therapeutics AB

()-

Thank you very much, and welcome to Calliditas Q4 2020 report. And if you -- as you're aware, obviously, there is a disclaimer. And so during today's call, we'll be making certain forward-looking statements may include statements among other things about the timing progress of results. Our ongoing Phase III clinical trials for Nefecon, development plan for setanaxib or any other future product candidates, timing, scope, likelihood, domestic, and/or foreign regulatory filings and approvals. Those forward-looking statements are based on current information assumption and expectations, are subject to change. And involve risks and uncertainties that may cause the actual results to differ materially from those contained in the forward-looking

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.